Log In
Print this Print this

lunacalcipol (CTA018, MT-2832)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionVitamin D analog that inhibits CYP24 and activates vitamin D receptor (VDR)-mediated gene regulation
Molecular Target Not available
Mechanism of ActionVitamin D receptor (VDR) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationThyroid disease
Indication DetailsTreat secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today